Video

5-Year Follow-Up Data For CPX-351 in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Related Content
Chronic leukemia cells in blood -- Image credit: Dr_Microbe | stock.adobe.com
June 11th 2025

ASCO 2025: Asciminib Demonstrates Superiority Compared With Nilotinib in Ph+ CML-CP

Gillian McGovern, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
3D visualization of white blood cells | Image Credit: © stockdevil - stock.adobe.com
June 4th 2025

Fixed-Duration Ibrutinib Plus Venetoclax Shows Long-Term Efficacy in First-Line CLL/SLL Treatment

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

3D visualization of multiple myeloma cells | Image Credit: © AImmersive Imagery - stock.adobe.com
June 3rd 2025

From MGUS to Myeloma: Understanding and Interrupting Disease Progression

Alexandra Gerlach, Associate Editor
Visualization of myeloma cells in bone marrow | Image Credit: © Khella - stock.adobe.com
June 1st 2025

MRD Monitoring May Help Redefine Long-Term Goals in Myeloma Therapy

Alexandra Gerlach, Associate Editor